Literature DB >> 32182368

Insulin Autoimmune Syndrome: A Case of Clopidogrel-induced Autoimmune Hypoglycemia.

Genevieve L Calder1, Glenn M Ward1, Nirupa Sachithanandan1, Richard J MacIsaac1.   

Abstract

CONTEXT: Insulin autoimmune syndrome (IAS) is characterized by hyperinsulinemic hypoglycemia with elevated anti-insulin antibodies. Most commonly observed in the Japanese population, elsewhere it is rare and associated with autoimmune diseases, plasma cell dyscrasias, or sulfhydryl group medications. The active metabolite of clopidogrel has a sulfhydryl group and here we report a case of clopidogrel-induced IAS. CASE DESCRIPTION: A 67-year-old man was admitted with severe hyperinsulinemic hypoglycemia requiring continuous intravenous infusion of 10% dextrose to sustain euglycemia. His symptoms of hypoglycemia had started after commencing dual antiplatelet therapy (including clopidogrel) for ischemic heart disease 9 months earlier. The hypoglycemia was associated with elevated insulin, proinsulin, c-peptide, and anti-insulin antibody titers as well as the HLA-DRB1*04 haplotype. Multiple localizing studies were negative for an insulinoma. A diagnosis of IAS was thus made. Clopidogrel cessation, oral dexamethasone, and diazoxide therapy were not sufficient to safely wean the dextrose infusion. Plasma exchange was ultimately effective.
CONCLUSIONS: This case highlights a case of severe IAS. Given the ubiquity of clopidogrel, IAS should be remembered as a rare adverse effect. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  clopidogrel; hypoglycemia; insulin autoimmune syndrome

Mesh:

Substances:

Year:  2020        PMID: 32182368     DOI: 10.1210/clinem/dgz301

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  1 in total

Review 1.  Case Report: Recurrent Autoimmune Hypoglycemia Induced by Non-Hypoglycemic Medications.

Authors:  Qiuping Zhu; Hanxin Zhao; Wei Qiu; Fang Wu; Chungen Qian; Yonghong Yang; Ye Kang; Fenping Zheng; Jiaqiang Zhou
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.